CHAPTER 1 - MARKET SUMMARY
Market Overview
The KSA Soft Gelatin Capsules Market operates across pharmaceutical, nutraceutical, cosmeceutical and veterinary formulations, with revenue recognized at the finished-dose manufacturer or importer level. Saudi Arabia had 35.3 million residents in 2024, creating a large consumption base for vitamin D, omega-3, analgesic and gastrointestinal softgels. Scale matters commercially because higher batch volumes improve rotary-die utilization and reduce per-capsule conversion costs.
Riyadh, Jeddah and the Eastern Province form the principal demand and distribution hubs because they combine dense pharmacy networks, major hospitals, import gateways and pharmaceutical manufacturing assets. The national healthcare supply chain included 56 licensed and registered pharmaceutical facilities in 2024. Concentration around these hubs supports faster inventory turns, centralized tender participation and lower temperature-controlled distribution costs.
Market Value
USD 230 million
2025
Dominant Region
Riyadh Region
2025
Dominant Segment
Nutraceutical Applications
fastest growing
Total Number of Players
42
Future Outlook
The KSA Soft Gelatin Capsules Market is projected to expand from USD 230 million in 2025 to USD 325 million by 2031, representing a 5.93% forecast CAGR after 6.23% historical growth during 2020-2025. Growth will be volume-led, with finished capsule demand rising from 3.60 billion units to 4.88 billion units. Nutraceutical products, especially vitamin D, omega-3, coenzyme Q10 and multivitamin formulations, will remain the largest incremental revenue pool. Pharmaceutical localization will also support domestic contract manufacturing, while SFDA harmonization will favor suppliers able to document gelatin origin, dissolution performance, stability and halal compliance across multiple product registrations.
Value growth will moderately outpace unit growth as formulation complexity increases and manufacturers adopt enteric coatings, solubility-enhanced lipid systems and vegetarian shell platforms. Plant-based and fish-gelatin formats are expected to gain share, but bovine gelatin will retain scale advantages in mainstream products. Riyadh will remain the principal commercial hub, while Jeddah benefits from import logistics and the Eastern Province from industrial capacity. The 2031 outcome assumes stable regulatory timelines, continued healthcare coverage and gradual localization. Downside risk centers on imported input costs and delayed dossier approvals; upside depends on export-oriented capacity, private-label nutraceutical demand and faster e-pharmacy penetration.
5.93%
Forecast CAGR
$325 Mn
2030 Projection
Base Year
2025
Historical Period
2020-2025
Forecast Period
2026-2031
Historical CAGR
6.23%
CHAPTER 2 - SCOPE OF REPORT
Scope of the Market
CHAPTER 3 - Key Stakeholders
Key Target Audience
Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning.
Investors
CAGR, capacity utilization, localization economics, regulatory risk
Corporates
formulation pipeline, gelatin sourcing, batch economics, channel access
Government
pharmaceutical localization, halal compliance, supply security, affordability
Operators
rotary-die yield, drying cycle, leakage, dissolution performance
Financial institutions
equipment finance, working capital, covenant resilience, demand stability
CHAPTER 4 - Market Size & Growth
Market Size, Growth Forecast and Trends
This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers.
Historical & Projected Market Size ($ Million)
Year-over-Year Growth Rate (%)
Market Value vs Volume Growth (%)
Historical Market Performance (2020-2025)
Historical performance was resilient, with the market increasing from USD 170 million in 2020 to USD 230 million in 2025. The strongest annual expansion occurred in 2022 at 7.2%, reflecting sustained supplement consumption and normalization of pharmacy traffic after pandemic disruption. Growth moderated to 5.5% in 2025 as imported gelatin and freight costs stabilized. Volume rose from 2.77 billion to 3.60 billion capsules, while implied ASP increased from USD 0.0614 to USD 0.0639 per capsule, showing that utilization and mix, rather than sharp price inflation, drove most historical value creation.
Forecast Market Outlook (2026-2031)
Forecast growth remains steady rather than speculative, with a 5.93% CAGR lifting market value to USD 325 million by 2031. Annual growth is expected to remain within 5.5%-6.2%, supported by larger nutraceutical batches, local private-label programs and higher-complexity pharmaceutical fills. Capsule volume is projected to reach 4.88 billion units, while implied ASP rises to USD 0.0666. The base-year sizing carries an internal confidence range of USD 211-252 million, with the widest uncertainty linked to imported finished-dose allocation, unreported private-label sales and the boundary between consumer supplements and pharmaceutical softgels.
CHAPTER 5 - Market Data
Market Breakdown
The market's 2020-2031 trajectory reflects a combination of steadily rising capsule consumption, modest price and mix uplift, and faster adoption of non-animal shell systems. For CEOs and investors, the key issue is not headline growth alone, but which formulations can sustain regulatory compliance, batch efficiency and channel access.
Year | Market Size (USD Mn) | YoY Growth (%) | Capsule Volume (Bn Units) | Average Selling Price (USD/Capsule) | Plant-Based Share (%) | Period |
|---|---|---|---|---|---|---|
| 2020 | $170 Mn | +- | 2.77 | 0.0614 | Forecast | |
| 2021 | $181 Mn | +6.5% | 2.91 | 0.0622 | Forecast | |
| 2022 | $194 Mn | +7.2% | 3.07 | 0.0632 | Forecast | |
| 2023 | $206 Mn | +6.2% | 3.24 | 0.0636 | Forecast | |
| 2024 | $218 Mn | +5.8% | 3.42 | 0.0637 | Forecast | |
| 2025 | $230 Mn | +5.5% | 3.60 | 0.0639 | Forecast | |
| 2026 | $244 Mn | +6.1% | 3.79 | 0.0644 | Forecast | |
| 2027 | $259 Mn | +6.1% | 3.99 | 0.0649 | Forecast | |
| 2028 | $275 Mn | +6.2% | 4.20 | 0.0655 | Forecast | |
| 2029 | $291 Mn | +5.8% | 4.42 | 0.0658 | Forecast | |
| 2030 | $307 Mn | +5.5% | 4.64 | 0.0662 | Forecast | |
| 2031 | $325 Mn | +5.9% | 4.88 | 0.0666 | Forecast |
Capsule Volume
3.60 billion units, 2025, Saudi Arabia. Volume growth improves rotary-die utilization and lowers conversion cost per capsule. Saudi Arabia's 2024 population reached 35.3 million, supporting a broad recurring-consumption base for vitamins, omega oils and chronic-care formulations.
Average Selling Price
USD 0.0639 per capsule, 2025, Saudi Arabia. Price realization depends increasingly on formulation complexity rather than commodity gelatin. GELITA notes that softgel gelatin typically uses 150-200 Bloom grades and can support fast, enteric or controlled-release performance, widening the premium-product opportunity.
Plant-Based Share
33.5%, 2025, Saudi Arabia. Non-animal formats reduce halal-source risk and support premium positioning, although process yields remain less standardized. Dox Pharma states that it was the first company in MENA to launch a vegetarian softgel, confirming local technology development rather than reliance only on imports.
CHAPTER 6 - Segmentation
Market Segmentation Framework
Comprehensive analysis across key dimensions providing insights into market structure, consumer preferences, and distribution patterns.
No of Segments
7
Dominant Segment
Product Type
Fastest Growing Segment
Technology
Product Type
Application
End User
Therapeutic Area
Distribution Channel
Technology
Geography
Key Segmentation Takeaways
Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, consumer preferences, and distribution patterns.
Product Type
Bovine gelatin softgels remain commercially dominant because they combine mature rotary-die process parameters, broad excipient compatibility and lower conversion costs at scale. The leading Level-2 pool is Bovine Gelatin Softgels, particularly in vitamin D, omega-3, coenzyme Q10 and analgesic products. Fish gelatin and plant-based systems are gaining relevance where halal traceability, premium claims or vegetarian positioning justify higher material and validation costs.
Technology
Technology is the fastest-growing segmentation dimension because buyers are shifting from standard immediate-release formats toward differentiated delivery performance. Solubility-Enhanced Lipid Systems are the leading incremental opportunity, especially for poorly water-soluble actives and premium nutraceuticals. Enteric-coated and sustained-release softgels can improve patient experience and product lifecycle value, but require stronger stability, dissolution and scale-up evidence for SFDA registration and commercial manufacturing.
CHAPTER 7 - Regional Analysis
Regional Analysis
Saudi Arabia ranks second among selected Middle East and Africa softgel peers by 2025 market value, behind South Africa but ahead of Turkey, the UAE and Jordan. Its position reflects a large pharmaceutical import base, 35.3 million residents, expanding local manufacturing and centralized public procurement that can accelerate scale once products are registered.
Focus Country Ranking
2nd
Focus Country Market Size
USD 230 Mn (2025)
Focus Country CAGR (2026-2031)
5.93%
Focus Country Ranking
2nd
Focus Country Market Size
USD 230 Mn (2025)
Focus Country CAGR (2026-2031)
5.93%
Regional Analysis (Current Year)
Market Position
Saudi Arabia's USD 230 million market ranks second in the peer set, supported by higher pharmaceutical spending and a larger population than neighboring GCC markets.
Growth Advantage
Saudi Arabia's 5.93% forecast CAGR exceeds the UAE's 4.8% and Turkey's 5.5%, positioning it as a regional growth challenger rather than a mature-volume market.
Competitive Strengths
The Kingdom combines 56 registered pharmaceutical facilities, centralized NUPCO procurement and domestic softgel capability, improving localization potential despite imported gelatin and finished-dose dependence.
CHAPTER 8 - INDUSTRY ANALYSIS
Growth Drivers, Challenges & Opportunities
Comprehensive analysis of key factors shaping the KSA Soft Gelatin Capsules Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments.
Growth Drivers
Preventive Health and Chronic-Disease Demand
- Diabetes affected 9.1% of adults (2024, Saudi Arabia), expanding the addressable pool for vitamin D, omega-3 and adjunct wellness formulations distributed through pharmacies.
- Life expectancy rose to 78.8 years (2024, Saudi Arabia), increasing the commercial relevance of easy-to-swallow dosage formats for older and chronic-care consumers.
- Basic healthcare coverage reached 95.9% of the total population (2024, Saudi Arabia), reinforcing prescription access and the pharmacy infrastructure through which softgel products are dispensed.
Population Scale and Pharmacy-Led Access
- The population reached 35.3 million (2024, Saudi Arabia), supporting nationally scaled manufacturing runs and recurring pharmacy demand across multiple therapeutic and wellness categories.
- Basic healthcare coverage reached 95.9% of residents (2024, Saudi Arabia), widening access to prescribed and pharmacist-recommended softgel formulations.
- NUPCO's Wasfaty network had more than 1,500 private pharmacies (2019, Saudi Arabia), demonstrating the scale benefits of integrated dispensing and procurement channels.
Localization and Manufacturing Capability
- Jamjoom Pharma reported SAR 1.3 billion revenue (2024, company), showing that domestic manufacturers have the financial scale to invest in specialized dosage forms.
- Dox Pharma was established in 2008 (Saudi Arabia) and specializes in soft gelatin capsules, proving that local niche manufacturing capability is commercially established.
- NUPCO reported national factories captured 27% of tender value (2019, Saudi Arabia), indicating that procurement design can materially reward localized pharmaceutical supply.
Market Challenges
Imported Raw-Material and Finished-Dose Exposure
- Saudi Arabia recorded a gelatin net-trade deficit of USD 4.88 million (2024, Saudi Arabia), making validated shell inputs sensitive to external suppliers and logistics.
- Germany supplied 119,131 kg of gelatin (2023, Saudi imports), creating concentration risk if qualification changes, freight disruption or source-document gaps affect availability.
- Pharmaceutical imports reached USD 8.21 billion (2024, Saudi Arabia), forcing manufacturers to hold more safety stock for gelatin, plasticizers and specialty oils and weakening cash conversion during registration delays.
Regulatory and Halal Traceability Burden
- Gelatin and collagen imports are permitted only from approved establishments (2026, Saudi Arabia), requiring source qualification and auditable animal-origin documentation.
- Softgel products must demonstrate shelf-life under storage conditions that can be as strict as below 25 degrees Celsius (registered product, Saudi Arabia), increasing packaging and distribution controls.
- NUPCO tenders require suppliers to be registered and qualified (current process, Saudi Arabia), adding commercial lead time beyond SFDA product authorization.
Scale-Up and Quality-Control Complexity
- Gelatin grades commonly use 150-200 Bloom strength (industry specification), and small raw-material variation can affect sealing, leakage and dissolution performance.
- Plant-based shells represented approximately 30.15% of Saudi revenue (2022, market benchmark), but alternative polymers require different drying and sealing parameters, complicating multi-format plants.
- Procaps added 1.8 billion capsules of annual capacity (2022, company expansion), illustrating the capital scale needed to compete efficiently in global softgel manufacturing.
Market Opportunities
Vegetarian and Fish-Gelatin Platforms
- a modeled rise from 33.5% share in 2025 to 41.5% in 2031 (Saudi Arabia) supports premium conversion fees and private-label pricing for vegetarian, traceable and allergen-sensitive claims.
- Dox Pharma reports the first vegetarian softgel launch in MENA (company claim, Saudi Arabia), showing that local specialists and pharmacy brands can shorten lead times versus imported finished products.
- non-animal formats held 30.15% of revenue (2022, Saudi Arabia), but wider adoption requires validated high-speed sealing, polymer sourcing and equivalent dissolution, stability and microbiological performance.
Localized Softgel Contract Manufacturing
- 56 pharmaceutical facilities (2024, Saudi Arabia) provide a client base for multi-customer CDMO lines that spread validation, tooling and quality-system costs across recurring contracts.
- national factories captured 27% of NUPCO tender value (2019, Saudi Arabia), indicating that investors and domestic manufacturers can gain from tender eligibility and shorter replenishment cycles.
- NUPCO operated 90,000 pallet positions across six warehouses (2019, Saudi Arabia), but softgel localization still needs technology transfer, trained engineers, qualified gelatin and predictable variation approvals.
Advanced Lipid-Based Drug Delivery
- softgels can dissolve within 20-30 minutes (industry benchmark), enabling solubility-enhanced and enteric products to command development fees and technology premiums beyond commodity conversion.
- gelatin specifications of 150-200 Bloom (industry benchmark) support tailored release performance, allowing branded manufacturers, CDMOs and excipient suppliers to capture value from patient-centric reformulations.
- Procaps added 1.8 billion capsules of annual capacity (2022, company), illustrating that advanced-delivery commercialization requires scale, formulation screening, stability packages and regulatory evidence.
CHAPTER 9 - Competitive Landscape
Competitive Landscape Overview
The market is moderately fragmented, with global softgel technology leaders competing against Saudi and regional manufacturers. Entry barriers center on rotary-die know-how, halal-source control, SFDA registration, stability evidence and minimum efficient batch scale.
Market Share Distribution
Top 5 Players
Market Dynamics
8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.
Company Name | Market Share | Headquarters | Founding Year | Core Market Focus |
|---|---|---|---|---|
Catalent | - | Tampa, United States | 2007 | Pharmaceutical softgel development, formulation and commercial manufacturing |
Aenova Group | - | Starnberg, Germany | 2008 | Global pharmaceutical and consumer-health softgel contract manufacturing |
Lonza | - | Basel, Switzerland | 1897 | Capsule technologies, formulation ingredients and dosage-form solutions |
Sirio Pharma | - | Shantou, China | 1993 | Nutraceutical softgels, gummies and integrated dosage-form development |
Procaps Group | - | Barranquilla, Colombia | 1976 | Advanced pharmaceutical softgels and integrated CDMO services |
Fuji Capsule | - | Fujinomiya, Japan | - | Prescription, OTC and nutraceutical soft capsule manufacturing |
Jamjoom Pharma | - | Jeddah, Saudi Arabia | - | Locally manufactured pharmaceutical and consumer-health softgels |
Dox Pharma | - | Riyadh, Saudi Arabia | 2008 | Specialized gelatin and vegetarian softgel manufacturing |
MS Pharma | - | Amman, Jordan | 1989 | Regional generic pharmaceuticals including soft gelatin capsules |
Soft Gel Technologies | - | Los Angeles, United States | - | Custom nutraceutical softgel formulations and branded ingredients |
Cross Comparison Parameters
The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.
Annual Softgel Output Capacity
SFDA-Registered Softgel Portfolio
KSA Softgel Revenue Growth
Softgel Gross Margin
Analysis Covered
Market Share Analysis:
Compares local revenue concentration across global and domestic softgel suppliers
Cross Comparison Matrix:
Benchmarks capacity, registrations, growth and margin performance across competitors
SWOT Analysis:
Assesses technology, compliance, sourcing and route-to-market advantages by company
Pricing Strategy Analysis:
Evaluates conversion pricing, premium technologies and channel-specific price realization dynamics
Company Profiles:
Reviews manufacturing footprint, softgel specialization, partnerships and Saudi market relevance
CHAPTER 10 - REPORT TOC
Table of Contents
Phase 1Market Assessment Phase
11
Chapters
Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.
Phase 2Go-To-Market Strategy Phase
15
Chapters
Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.
Complete Report Coverage
201+ detailed sections covering every aspect of the market
143
Assessment Sections
58
Strategy Sections
CHAPTER 11 - Our Approach
Research Methodology
Desk Research
- SFDA softgel registration database review
- Gelatin import-flow and pricing analysis
- Manufacturer capacity and portfolio mapping
- Pharmacy channel and tender assessment
Primary Research
- Softgel plant operations manager interviews
- Pharmaceutical formulation director consultations
- Regulatory affairs manager discussions
- Pharmacy category buyer interviews
Validation and Triangulation
- 368 respondent observations reconciled
- Imported and domestic volumes cross-checked
- Capsule ASP benchmarks normalized
- Forecast scenarios independently stress-tested
CHAPTER 12 - FAQ
FAQs
Still have questions?
Our research team is here to help you find the right solution
CHAPTER 13 - Related Research
Explore Related Reports
Expand your market intelligence with complementary research across regions and adjacent markets.
Regional/Country ReportsRelated market analysis across key regions
Related market analysis across key regions
Adjacent ReportsRelated markets and complementary research
Related markets and complementary research
500+
Market Research Reports
50+
Countries Covered
15+
Industry Verticals